Shenzhen, China recently hosted the 2nd Ambulatory Glucose Profile (AGP) and Digital Therapeutics (DTx) summit forum, bringing together domestic and international health experts to discuss the latest advances in diabetes management technology. Led by the National Innovation Center for Advanced Medical Devices and sponsored by the China AGP and DTx Digital Therapeutics R&D Center, the forum explored the application of AGP in precision diagnosis and treatment of diabetes, as well as the role of digital therapeutics in clinical practice decision-making.
Professor Ji Linong, the initiator of the Chinese AGP & DTx R&D Center, organized the summit forum, which featured experts from countries such as Slovenia, Australia, and Saudi Arabia. Topics discussed included AGP consensus, the Chinese diabetes patient database, artificial pancreas systems, and digital health management. Professor Andrej Janež from Slovenia highlighted China’s progress in AGP clinical practice, noting the development of a training program and the use of AI to enhance diagnosis and treatment decisions.
During the forum, the AGP&DTx International R&D Consortium was established to promote global collaboration and knowledge sharing in diabetes diagnosis and treatment. This initiative aims to standardize AGP clinical applications worldwide and enhance diabetes care on a global scale.
SIBIONICS, a company founded in 2015, is dedicated to the research and development of implantable medical devices. By integrating cutting-edge CGM technology with patient-centric designs, SIBIONICS strives to revolutionize personalized diabetes management solutions. With over 1,000,000 users worldwide, SIBIONICS is recognized for its reliability and innovation in the field of diabetes management.
The summit forum in Shenzhen showcased the latest advancements in diabetes management technology and emphasized the importance of collaboration among international experts to enhance global diabetes diagnosis and treatment practices. Through initiatives like the AGP&DTx International R&D Consortium, efforts are being made to standardize AGP applications and improve diabetes care worldwide.
For more information on the AGP&DTx Summit Forum, please visit the press image here: [Link to press image]
Source link
